Doxorubicin-Melphalan with and Without Cisplatin in Advanced Ovarian Cancer: Ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group

References

• Sigurdsson K., Aim P., Gullberg B. Prognostic factors in malignant epithelial ovarian tumours. Gynecol Oncol 1983; 15: 370–80
   PubMedGoogle Scholar
• Tropé C. Melphalan with and without doxorubicin in advanced ovarian cancer. Obstet Gynecol 1987; 70: 582–6
   PubMed Web of Science ®Google Scholar
• Ozols R. F., Young R. C. Chemotherapy of ovarian cancer. Semin Oncol 1984; 9: 251–6
   Google Scholar
• WHO handbook for reporting results of cancer treatment. World Health Organization, Geneva 1979
   Google Scholar
• Kaplan E. L., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–70
   PubMedGoogle Scholar
• Cox D. R. Regression models and life tables. J R Stat Soc Ser B 1972; 34: 187–220
   Web of Science ®Google Scholar
• Tropé C, Andersson H., Friberg L. Doxorubicin + Melphalan versus Doxorubicin + Melphalan + Cisplatin in a prospective randomized study in advanced ovarian cancer. XII World Congress of Gynecology and Obstetrics (FIGO). Rio de Janeiro 1988; 140, Abs.
   Google Scholar
• Gaducci A., Bruzzone M., Carino F., Ragni N., Rubagotti A., Conte P. Twelve year follow up of a randomized trial comparing Cisplatin and Cyclophosphamide in patients with advanced epithelial cancer. Int J Cancer 1996; 6: 286–90
   Google Scholar
• Gruppo Interregional Cooperativo Oncologico Ginecologia. Long-term results of a randomized trial comparing cisplatin, with cisplatin and cyclophosphamide, and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer. Gynecol Oncol 1992; 45: 115–7
   PubMedGoogle Scholar
• Hoskins W. J., Bundy B. N., Thigpen J. T., Omura G. G. The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 1992; 47: 159–66
   PubMed Web of Science ®Google Scholar
• Nejt J. P. Ovarian cancer treatment: Time for some hard thinking. Eur J Cancer 1991; 27: 680–1
   PubMedGoogle Scholar
• Friedlander M. L., Dembo A. J. Prognostic factors in ovarian cancer. Semin Oncol 1991; 18: 205–12
   PubMedGoogle Scholar
• Louie K. G., Ozols R. F., Myers C. E. Long-term survival results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol 1986; 4: 1579–85
   PubMed Web of Science ®Google Scholar
• Nejt J. P., van der Burg M. E., van Oosterom A. T. Combination chemotherapy in advanced ovarian carcinoma:the experience of The Netherlands Joint Study Group for Ovarian Cancer. Multimodal Treatment of Ovarian Cancer, P. F. Conte, N. Ragni, R. Rosso, J. B. Vermorken. Raven Press, New York 1989; 35–227
   Google Scholar
• Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA study. Gynecol Oncol 1990; 38: 203–9
   PubMed Web of Science ®Google Scholar
• Hó Ugberg T. Ovarian cancer. Treatment results, prognostic factors, and tumor marker surveillance. thesis. Linköping University, Fac of Health Sciences. 1992; 33
   Google Scholar
• Piver M. S., Baker T. The potential for optimal (⩽2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: A prospective study. Gynecol Oncol 1986; 24: 1–8
   PubMed Web of Science ®Google Scholar
• Heintz A. P. M., van Oosterom A. T., Trimbos JBMC, Schaberg A., van der Velde E. A., Nooy M. The treatment of advanced ovarian carcinoma: (I) Clinical variables associated with prognosis. Gyneol Oncol 1988; 30: 347–58
   PubMed Web of Science ®Google Scholar
• Hoskins P. J., Oreilly S. E., Swenerton K. D., Spinelli J. J., Fairey R. N., Benedet J. L. 10-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based mul-timodality therapy. J Clin Oncol 1992; 10: 1561–8
   PubMedGoogle Scholar
• Makar A., Baekelandt M., Tropé C, Kristensen G. The prognostic significance of residual disease, FIGO substage, tumor histology and grade in patients with FIGO Stage III ovarian cancer. Gynecol Oncol 1995; 56: 175–82
   PubMedGoogle Scholar
• Hacker N. F., Berek J. S., Lagasse L. D., Nieberg R. K., Elashoff R. M. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61: 413–20
   PubMed Web of Science ®Google Scholar
• Hunter R. W., Alexander N. D. E., Soutter W. P. Meta-analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis. Am J Obstet Gynecol 1992; 166: 504–11
   PubMed Web of Science ®Google Scholar
• Van der Burg M. E. L., van Lent M., Kobierska A. Intervention debulking surgery (IDS) does improve survival in advanced epithelial ovarian cancer (EOC); and EORTC gynecological cancer cooperative group (GCCG) study. ASCO May, 1993; 258
   Google Scholar
• Hoskins W., McGuire W., Brady M. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170: 974–80
   PubMed Web of Science ®Google Scholar
• Lippman S. M., Alberts D. S., Slymen D. J. Second-look laparotomy in epithelial ovarian carcinoma. Cancer 1988; 61: 2571–7
   PubMedGoogle Scholar
• Podraz K. Z., Malkasian G. D., Wieand H. S. Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol 1988; 29: 274–82
   PubMedGoogle Scholar
• Nejt J. P., ten Bokkel Huinink W. W., van der Burg M. E. L. Randomized trial comparing two combination chemotherapy regimens (CHAP-5v) in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157–68
   PubMedGoogle Scholar
• Cain J. M., Saigo P. E., Pierce V. K. A review of second-look laparotomy for ovarian cancer. Gynecol Oncol 1986; 23: 14–25
   PubMed Web of Science ®Google Scholar
• Sutton G. P., Stehman F. B., Einhorn L. H., Roth L. M., Blessing J. A., Ehrlich C. E. Ten-year follow-up of patients receiving cisplatin, doxorubicin and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 1989; 7: 223–9
   PubMed Web of Science ®Google Scholar
• Nejt J. P., ten Bokkel Hunink W. W., van der Burg M. E. L. Long-term survival in ovarian cancer. Eur J Cancer 1991; 27: 1367–72
   PubMedGoogle Scholar
• Sorbe B., Trope C., Nordal R. Chemotherapy versus radiotherapy as consolidation treatment of ovarian carcinomas stage III at surgical complete remission from induction chemotherapy. Proc ASCO 1996; 15: 780
   Google Scholar
• Bertelsen K., Hansen M. K., Pedersen PH. The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer. Br J Obstet Gynecol 1988; 95: 1231–6
   PubMedGoogle Scholar
• Luesley D., Blackledge G., Kelly K. Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet 1988; 2: 599–603
   PubMed Web of Science ®Google Scholar
• Stanhope R., Smith J., Ruthledge F. Second trial drugs in ovarian cancer. Gynecol Oncol 1977; 5: 52–5
   PubMed Web of Science ®Google Scholar
• The Ovarian Cancer Meta-Analysis Group. Cyclophosphamide plus cisplatin versus cyclophosphamide doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a metaanalysis. J Clin Oncol 1991; 9: 1668–74
   PubMedGoogle Scholar
• A'Hern R. P., Gore M. E. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 32–726
   Google Scholar
• McGuire W. P., Hoskins W. J., Brady M. F. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1
   PubMed Web of Science ®Google Scholar